News
November 10, 2021
Presentation at 14th CTAD Conference November 10, 2021
EIP Pharma announces that final results of the AscenD-LB phase 2 clinical study demonstrates neflamapimod has disease-modifying potential in dementia with Lewy Bodies Results presented at 14th Clinical Trials in Alzheimer’s Disease (CTAD) meeting in Boston Neflamapimod treatment led to significant improvement relative to placebo in cognition, motor function, and cognition & function […]
Read MoreNovember 4, 2021
EIP Pharma Announces New Data Presentations from Phase 2 Treatment Trial in Dementia with Lewy Bodies at Upcoming Scientific Conference and New Board Appointment
Final results of the AscenD-LB clinical study informs on disease-modifying potential of neflamapimod in dementia with Lewy bodies Presentations at 14th Clinical Trials in Alzheimer’s Disease Meeting, November 9-12, 2021 BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces that the […]
Read More
EIP Pharma appoints Dr. Marwan Sabbagh to Board of Directors
As an internationally recognized dementia clinical expert, Dr. Sabbagh brings deep knowledge of disease, patient management and clinical trial experience BOSTON, Nov. 4, 2021 /PRNewswire/ — EIP Pharma Inc., a clinical-stage pharma company focused on the development of disease-modifying treatments for dementia and neurodegenerative diseases announces the appointment of Dr. Marwan Sabbagh as non-executive director to its Board of Directors […]
Read MoreView All News
Presentations
View All Presentations
About EIP
Are you a patient, caregiver, clinician or professional and want to learn more about EIP Pharma’s approach? Please contact us.
Contact Us